Roth Capital started coverage on shares of Bluebird Bio Inc. (NASDAQ:BLUE) in a research note issued to investors on Thursday. The brokerage set a “buy” rating and a $87.00 price target on the stock. Roth Capital’s target price points to a potential upside of 17.87% from the company’s previous close.

Several other research analysts have also weighed in on the company. Goldman Sachs Group Inc. reissued a “buy” rating and issued a $135.00 price objective on shares of Bluebird Bio in a research report on Thursday, August 18th. Zacks Investment Research raised Bluebird Bio from a “sell” rating to a “hold” rating in a research report on Monday, August 8th. BTIG Research reaffirmed a “buy” rating and issued a $72.00 target price on shares of Bluebird Bio in a research report on Wednesday, June 29th. Jefferies Group reaffirmed a “positive” rating and issued a $80.00 target price on shares of Bluebird Bio in a research report on Thursday, July 14th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $117.00 target price on shares of Bluebird Bio in a research report on Wednesday, August 3rd. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $89.17.

Analyst Recommendations for Bluebird Bio (NASDAQ:BLUE)

Shares of Bluebird Bio (NASDAQ:BLUE) traded down 2.06% during mid-day trading on Thursday, reaching $72.29. The company had a trading volume of 271,612 shares. The stock’s market capitalization is $2.69 billion. The firm’s 50 day moving average is $57.02 and its 200-day moving average is $48.11. Bluebird Bio has a 12-month low of $35.37 and a 12-month high of $113.26.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/bluebird-bio-inc-blue-earns-buy-rating-from-analysts-at-roth-capital.html

Bluebird Bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by $0.15. The company had revenue of $1.55 million for the quarter, compared to the consensus estimate of $2.01 million. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The firm’s revenue for the quarter was down 68.6% on a year-over-year basis. During the same period in the prior year, the business earned ($1.57) earnings per share. On average, analysts expect that Bluebird Bio will post ($6.16) earnings per share for the current fiscal year.

In other news, insider Eric Sullivan sold 2,912 shares of the company’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $55.01, for a total value of $160,189.12. Following the transaction, the insider now owns 4,456 shares of the company’s stock, valued at $245,124.56. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider David Davidson sold 1,000 shares of the company’s stock in a transaction on Friday, July 15th. The stock was sold at an average price of $45.08, for a total transaction of $45,080.00. Following the completion of the transaction, the insider now directly owns 10,600 shares in the company, valued at approximately $477,848. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by insiders.

A number of hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP acquired a new stake in Bluebird Bio during the first quarter valued at about $51,095,000. BlackRock Inc. raised its stake in Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock valued at $194,000 after buying an additional 3,533 shares during the last quarter. California State Teachers Retirement System raised its stake in Bluebird Bio by 2.2% in the second quarter. California State Teachers Retirement System now owns 77,687 shares of the company’s stock valued at $3,363,000 after buying an additional 1,682 shares during the last quarter. Iguana Healthcare Management LLC acquired a new stake in Bluebird Bio during the first quarter valued at about $1,030,000. Finally, Swiss National Bank raised its stake in Bluebird Bio by 10.6% in the second quarter. Swiss National Bank now owns 59,707 shares of the company’s stock valued at $2,585,000 after buying an additional 5,700 shares during the last quarter.

About Bluebird Bio

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

5 Day Chart for NASDAQ:BLUE

Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.